Candel TherapeuticsCADL
CADL
About: Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Employees: 38
0
Funds holding %
of 7,310 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
255% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 11
118% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 11
66% more call options, than puts
Call options by funds: $4.4M | Put options by funds: $2.65M
17% more funds holding
Funds holding: 70 [Q4 2024] → 82 (+12) [Q1 2025]
2.65% more ownership
Funds ownership: 42.21% [Q4 2024] → 44.86% (+2.65%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
23% less capital invested
Capital invested by funds: $156M [Q4 2024] → $120M (-$35.8M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$19
281%
upside
Avg. target
$21
321%
upside
High target
$23
361%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andrew Fein | 361%upside $23 | Buy Assumed | 30 Jun 2025 |
HC Wainwright & Co. Vernon Bernardino | 281%upside $19 | Buy Reiterated | 11 Apr 2025 |
Financial journalist opinion
Based on 7 articles about CADL published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know
Candel Therapeutics (CADL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Proactive Investors
1 week ago
Candel Therapeutics announces $15M direct offering to support CAN-2409 launch preparations
Candel Therapeutics Inc (NASDAQ:CADL) has announced a $15 million registered direct offering of common stock, the proceeds of which will support launch readiness, medical affairs, and pre-commercialization activities, as well as preparation for a Biologics License Application (BLA) submission for CAN-2409 in prostate cancer, expected in the fourth quarter of 2026. “We are pleased to strengthen our financial position with the resources intended to support pre-commercialization and launch readiness activities for CAN-2409 in prostate cancer, pending regulatory approval, as well as other key corporate purposes,” Candel CEO Dr Paul Peter Tak said.
Neutral
GlobeNewsWire
1 week ago
Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
NEEDHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, has agreed to sell approximately 3.2 million shares of its common stock (Common Stock) to a select group of accredited investors in a registered direct offering (the Offering), at a price per share of $4.67. The Offering is expected to close on June 25, 2025, subject to the satisfaction of customary closing conditions. Gross proceeds from the Offering are expected to be approximately $15.0 million, before deducting offering-related expenses payable by the Company.
Neutral
Proactive Investors
1 week ago
Candel Therapeutics names Charles Schoch as CFO after interim tenure
Candel Therapeutics Inc (NASDAQ:CADL) announced that it has appointed Charles Schoch as its chief financial officer. Schoch had served as interim CFO since January 2024 and is being elevated to the permanent position following a key period of operational and financial execution, the company said on Monday.
Neutral
GlobeNewsWire
1 week ago
Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financial milestones Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financial milestones
Positive
Proactive Investors
3 weeks ago
Candel Therapeutics adds biotech veteran Maha Radhakrishnan to Board
Candel Therapeutics Inc (NASDAQ:CADL) has appointed biotechnology industry veteran Maha Radhakrishnan, M.D., to its board of directors.
Neutral
GlobeNewsWire
3 weeks ago
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development
Positive
Zacks Investment Research
1 month ago
Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 285.3% in Candel Therapeutics (CADL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
1 month ago
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
Candel stock rises as FDA grants RMAT tag to CAN-2409 after phase III success in prostate cancer. BLA submission is planned at the end of 2026.
Positive
Proactive Investors
1 month ago
Candel Therapeutics get FDA's RMAT designation for prostate cancer therapy
Candel Therapeutics Inc (NASDAQ:CADL) said on Wednesday the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead immunotherapy candidate, CAN-2409, for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease. The RMAT designation is intended to expedite the development and review of regenerative therapies for serious conditions where preliminary evidence suggests the drug may address unmet medical needs.
Charts implemented using Lightweight Charts™